Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi to Acquire Inhibrx Assets for up to $2.2B | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sanofi to Acquire Inhibrx Assets for up to $2.2B

Inhibrx's non-101 discovery pipeline will be spun out into a new company, Inhibrx Biosciences, Inc.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi has entered into a definitive agreement under which its subsidiary Aventis Inc. will acquire all assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin (AAT) augmentation therapy currently in a registrational trial for the treatment of alpha-1 antitrypsin deficiency (AATD). 
 
Inhibrx is a clinical-stage biopharmaceutical company focused on developing biologic therapeutic candidates in oncology and orphan diseases leveraging its protein engineering platforms.

Inhibrx’s non-101 discovery pipeline, including INBRX-105, INBRX-106, INBRX-109, and its corporate infrastructure, will be spun out from the company into a new company, Inhibrx Biosciences, Inc.
 
Sanofi will acquire all outstanding shares of Inhibrx through a merger in an aggregate transaction value of approximately $2.2 billion. Inhibrx will be led by Mark Lappe as Chairman and CEO, as well as the other members of the current management team of Inhibrx. 
 
Sanofi’s acquisition of Inhibrx is subject to the completion of the new Inhibrx spin-off transaction and other customary closing conditions.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics